CytRx publishes results from Arimoclomol Phase 2 trial for sIBM
Category: #health  By Saipriya Iyer  Date: 2020-02-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

CytRx publishes results from Arimoclomol Phase 2 trial for sIBM

CytRx Corporation, a biopharmaceutical firm that specializes principally in neurodegenerative and oncology diseases, recently announced its data from Orphazyme double-blinded Phase 2 study of arimoclomol for the treatment of sIBM (Sporadic Inclusion Body Myositis).

Reportedly, the study was a 24-patient randomized pilot (with 8 patients on placebo and 16 on arimoclomol) where almost 83% of patients receiving treatment from arimoclomol were stabilized whereas 25% managed to be stabilized in placebo.

Orphazyme trial is expected to be completed by the end of 2020, with interim analysis coming in the first half of 2020. Moreover, the results from this study are slated to be revealed by the first half of 2021, with regulatory submission being submitted by the second half of 2021.

Speaking on the move, Eric Curtis, President and Chief Operating Officer, CytRx, said that the company is with the findings of Phase 2 clinical study treating sIBM with arimoclomol. Moreover, it is projected that there are nearly 40,000 patients in Europe and the USA who go through this debilitating disease and presently there are no effective therapies for this massive population of sIBM patients.

Incidentally, CytRx has also announced that Orphazyme A/S licensed arimoclomol has completed a major new capital raise of around $110 million for expansion. Orphazyme claims that the funding will support the finalization of arimoclomol's clinical advancements in sIBM and help prepare regulatory filings in Europe and possibly in the U.S.

The investment also offers noteworthy cash for Orphazyme to further arimoclomol towards commercialization in NPC. Orphazyme also aims at using the proceeds to cover the completion of clinical development of arimoclomol in ALS.

Reports claim that CytRx is eligible to receive over $120 million in future milestones, along with royalties, from the company’s arimoclomol licensing deal. If received, the investment would secure a minimum of $250 million in net operating losses.

Source Credit: https://cytrxcorporation.gcs-web.com/news-releases/news-release-details/cytrx-corporation-highlights-recently-published-data-its?field_nir_news_date_value%5Bmin%5D=2017&items_per_page=10#views-exposed-form-widget-news-widget-news-ul



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...